Navigation Links
Jazz Pharmaceuticals Announces Public Offering of Ordinary Shares by Selling Shareholders
Date:3/5/2012

s by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health. The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' proposed public offering of ordinary shares, the anticipated proceeds from the offering, and the completion, timing and size of the offering. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the heading "Risk Factors" in the Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which Jazz Pharmaceuticals filed with the SEC on February 28, 2012 on behalf of and as successor to Jazz Pharmaceuticals, Inc., and in its other filings with the SEC. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
2. Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors
3. Avanir Pharmaceuticals to Participate in Two Conferences in March
4. Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value
5. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
7. Cumberland Pharmaceuticals Reports 2011 Annual Financial Results
8. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
10. Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System
11. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... York , July 30, 2015 ... its latest report titled, "Continuous Glucose Monitoring Systems Market: ... According to the report, the global continuous glucose monitoring ... 2014 and is expected to reach US$ 788.4 Mn ... forecast period, 2015 to 2020. Global continuous ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... The National Community Pharmacists Association (NCPA) expressed strong ... launched by the U.S. Senate Special Committee on ... Pharmalot . (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... response, NCPA President Joseph H. Harmison, PD and Arlington, ...
... premier provider of economic ultrasound solutions, today announced the ... proprietary repair technology not previously available in the U.S. ... repair services designed to counter a growing emphasis in ... industry has been moving away from repairing customers, probes ...
Cached Medicine Technology:NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare 2MedPro Imaging Launches Ultrasound Transducer Repair Division 2
(Date:7/31/2015)... ... ... Girl Scouts of Historic Georgia and Peach State Health Plan are teaming ... Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check for ... our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are very ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The 2015 ALS ... Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn ... MLB is donating $100,000 to further collaborative efforts among the ALS organizations to find ...
(Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
(Date:7/31/2015)... NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ... op. , Glancing out of the window, he recalled that his equipment was set ... Chrystie Street tower, he jumped out of bed. , The photo speaks for itself. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... GPRO ) announced today that the Company will release ... 2008 at approximately,4:00 p.m. Eastern Time (ET). The announcement ... ET. Henry L. Nordhoff, chairman and chief,executive officer, and ... will host the call., The conference call will ...
... of $350K will Target Easter Seals Affiliates Nationwide, ... the emerging,challenges of people living with autism during April,s ... $350,000 in grants this,month from the CVS Caremark Charitable ... million to support Easter Seals autism services,nationwide. These grants ...
... heart, lungs and liver, study suggests , , THURSDAY, April ... fatty plaques that harden arteries may also harm vital ... formation in arteries," said study author Rita K. Upmacis, ... at Weill Medical College of Cornell University in New ...
... Decline Even Though Everyone Benefits ... Forget to Claim The Deduction!, NEW YORK, April 10 ... a timely reminder that donating your car is,still a great way ... that because the number of vehicle donations has plummeted -- and,charities ...
... with this method, researchers find , , THURSDAY, ... and vegetables can reduce the risk of food ... bacteria, new research shows. , The study suggests ... the U.S. Food and Drug Administration, can kill ...
... NEW YORK, April 10 Methodist Healthcare -- Memphis,Hospitals ... tender offer for certain designated maturities of the,Bonds. The ... was set to,expire on April 9, 2008 at 5:00 ... the tender offer will be terminated is applicable to,the ...
Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 2Health News:Easter Seals Receives $1 Million Donation From CVS Caremark Charitable Trust to Enhance Autism Services for Children 3Health News:Atherosclerosis May Also Harm Vital Organs 2Health News:Atherosclerosis May Also Harm Vital Organs 3Health News:Tax Season Reminder: Vehicle Donations Still Needed 2Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2
Immersion Oil, 1,250 cs...
Immersion oil for microscopy...
... system is a compact, convenient and precise ... a significant improvement in life quality through ... condition. , , The CoaguChek XS system ... CoaguChek S system. It encompasses several innovative ...
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
Medicine Products: